Caseware UK (AP4) 2024.0.164 2024.0.164 2024-10-312024-10-31true2023-11-01falseNo description of principal activity10truefalse 13707256 2023-11-01 2024-10-31 13707256 2022-11-01 2023-10-31 13707256 2024-10-31 13707256 2023-10-31 13707256 c:Director1 2023-11-01 2024-10-31 13707256 d:CurrentFinancialInstruments 2024-10-31 13707256 d:CurrentFinancialInstruments 2023-10-31 13707256 d:ShareCapital 2024-10-31 13707256 d:ShareCapital 2023-10-31 13707256 c:OrdinaryShareClass1 2023-11-01 2024-10-31 13707256 c:OrdinaryShareClass1 2024-10-31 13707256 c:OrdinaryShareClass1 2023-10-31 13707256 c:EntityHasNeverTraded 2023-11-01 2024-10-31 13707256 c:FRS102 2023-11-01 2024-10-31 13707256 c:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 13707256 c:FullAccounts 2023-11-01 2024-10-31 13707256 c:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 13707256 e:PoundSterling 2023-11-01 2024-10-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 13707256









VITONNIX UK HEALTHCARE LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 OCTOBER 2024

 
VITONNIX UK HEALTHCARE LIMITED
REGISTERED NUMBER: 13707256

BALANCE SHEET
AS AT 31 OCTOBER 2024

2024
2023
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 3 
1,000
1,000

  
1,000
1,000

Total assets less current liabilities
  
 
 
1,000
 
 
1,000

  

Net assets
  
1,000
1,000


Capital and reserves
  

Called up share capital 
 4 
1,000
1,000

  
1,000
1,000


For the year ended 31 October 2024 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 27 June 2025.




Prashant Jindal
Director

The notes on page 2 form part of these financial statements.

Page 1

 
VITONNIX UK HEALTHCARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

1.


General information

The Company is a private company, limited by shares, incorporated and domiciled in England within the United Kingdom, registration number 13707256.  The Company's registered office is 21 Oldway Drive, Solihull, England, B91 3HP.
The financial statements are presented in sterling which is the functional currency of the company and the financial statements are rounded to the nearest £1.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

Cash flow
Under Financial Reporting Standard 102, the company is exempt from the requirement to prepare a cash flow statement on the grounds that it qualifies as a small company.

 
2.2

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.


3.


Debtors

2024
2023
£
£


Called up share capital not paid
1,000
1,000

1,000
1,000



4.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



1,000 (2023 - 1,000) Ordinary shares of £1.00 each
1,000
1,000


Page 2